Surge, a private equity firm, completed the $200m investment in Elite Clinical Network, an integrated platform currently operating a network of phase I-IV clinical research sites. “We are impressed with the success that management has achieved to date and are excited to partner with CEO David Wilson III to support the next phase of building a national network. With a very high new site launch growth rate, multi-decade customer relationships, strong industry tailwinds, and a significant diversified backlog, ECN is well positioned to continue its expansion as a dominant player in the clinical trial industry,” Sanjay Gulati, Surge Principal.